ImmuneAGE Bio is a technology company.
ImmuneAGE Bio has raised $2.0M across 1 funding round.
Key people at ImmuneAGE Bio.
ImmuneAGE Bio was founded by Sebastian Brunemeier (CEO & Founder).
ImmuneAGE Bio has raised $2.0M in total across 1 funding round.
Key people at ImmuneAGE Bio.
ImmuneAGE Bio was founded by Sebastian Brunemeier (CEO & Founder).
ImmuneAGE Bio has raised $2.0M in total across 1 funding round.
ImmuneAGE Bio's investors include Andreessen Horowitz, Anorak Ventures, Ground Up Ventures, Ludlow Ventures, Motier Ventures, Octopus Ventures, Pareto Holdings, Volt Capital, Austin Ogilvie, Balaji Srinivasan.
ImmuneAGE Bio is a preclinical biotech startup developing the first drug discovery platform for immune system rejuvenation by targeting hematopoietic stem cells (HSCs) in the bone marrow.[1][2][3] Its core technologies include the StemSupply platform for over 1,000x expansion of HSCs and the AgeScreen geroscience drug discovery engine, enabling identification of molecules like lead compound IA101—a non-toxic small molecule that rejuvenates aged HSCs with superior efficacy to prior compounds.[1][2][3] The company serves an aging global population by addressing immune decline, aiming to boost resilience against pandemics, cancer, and age-related diseases through "Immune Refresh Therapy"—a potential outpatient procedure using patients' own expanded and rejuvenated HSCs.[1][4] Backed by $2M in initial funding and VitaDAO's $50K investment, ImmuneAGE shows early momentum with prestigious investors like Balaji Srinivasan and Thomas Ebeling, plus a seed round underway as of mid-2024.[2][3][4]
ImmuneAGE Bio emerged from stealth in July 2024, founded by Sebastian Brunemeier, MSc, a serial longevity entrepreneur previously co-founder and CIO at Cambrian Biopharma, founder/COO at Samsara Therapeutics, and investor at Apollo Health Ventures and Healthspan Capital.[1][3][4] The idea stemmed from Brunemeier's expertise in longevity science (Oxford, University of Amsterdam) and recognition that transplanting young bone marrow into aged mice extends lifespan by ~30%—the largest effect of any intervention—highlighting HSCs as the immune system's aging root.[3][4] Pivotal early traction came via VitaDAO funding in April 2023 for IA101 development, de-risked by analogs' human trial safety data, with scientific co-founders like Nicola Vannini (University of Lausanne) and collaborators at Oxford (Adam Wilkinson).[2][3] The team expanded with Josef Christensen, PhD (ex-McKinsey, Novo Nordisk, StemMedical) as COO, Stephan Emmrich, PhD as Director of Immunology, and Ryan Spangler as Director of Operations.[1][2][3]
ImmuneAGE rides the geroscience and longevity biotech wave, focusing solely on immune aging—the systemic driver of frailty, cancer, and pandemics vulnerability—as HSCs originate all immune cells.[1][2][4] Timing aligns with aging populations (e.g., rising over-65 demographics) and post-COVID emphasis on immune resilience, plus advances in stem cell tech de-risking therapies.[3][4] Market tailwinds include $2M seed validating preclinical proof-of-concept, VitaDAO's decentralized biofunding model accelerating discovery, and regulatory precedents from HSC analogs.[2][3] ImmuneAGE influences the ecosystem by pioneering HSC-scale screening, potentially enabling "always-available" bone marrow donors and healthier lifespans, bridging academia (Oxford/Lausanne) with pharma-scale development.[1][4]
ImmuneAGE is poised for seed-round acceleration into IND-enabling studies for IA101, targeting "Immune Refresh" as a periodic outpatient therapy to extend healthspan.[3][4] Rising geroscience investment, AI-drug discovery synergies, and regulatory nods for cellular rejuvenation (e.g., stem cell approvals) will shape its path, with potential partnerships from big pharma eyeing immune platforms.[2][3] Its influence could evolve from niche longevity pioneer to ecosystem shaper, proving immune reboot maximizes productive years—echoing its mission to reboot the immune system at its source.[1][4]
ImmuneAGE Bio has raised $2.0M across 1 funding round. Most recently, it raised $2.0M Seed in July 2024.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jul 1, 2024 | $2.0M Seed | Andreessen Horowitz, Anorak Ventures, Ground Up Ventures, Ludlow Ventures, Motier Ventures, Octopus Ventures, Pareto Holdings, Volt Capital, Austin Ogilvie, Balaji Srinivasan |
